Cell therapy sector strengthens, Zhaoyan New Drug hits the daily limit

robot
Abstract generation in progress

March 27 news, as of 11:15, the cell therapy sector is strengthening, with Zhaoyan New Drug and Shuanglu Pharmaceutical hitting the limit up, and stocks like Tailin Biotech and Heng Rui Pharmaceutical seeing significant gains.

Statement: The market has risks, and investment should be cautious. This article is automatically published based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for discrepancies. For inquiries, please contact biz@staff.sina.com.cn.

A wealth of information and precise interpretations can be found in the Sina Finance APP.

Editor: Xiaolang Express Report

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin